Transaction in Own Shares

PureTech Health PLC
27 December 2023
 

27 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

22 December 2023



Number of ordinary shares purchased:

35,715



Highest price paid per share:

158.60p



Lowest price paid per share:

150.80p



Volume weighted average price paid per share:

152.90p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,614,428 ordinary shares in treasury and has 271,853,731 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 271,853,731 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

22/12/2023

08:13:02

279

151.8

CHIX

00383501662TRLO0.1.1

22/12/2023

08:13:02

32

152

CHIX

00383501663TRLO0.1.1

22/12/2023

08:15:39

279

151.8

CHIX

00383501962TRLO0.1.1

22/12/2023

08:15:39

20

152

CHIX

00383501963TRLO0.1.1

22/12/2023

08:17:59

279

151.8

CHIX

00383502239TRLO0.1.1

22/12/2023

08:18:01

208

151.8

BATE

00383502244TRLO0.1.1

22/12/2023

08:42:06

1016

152

XLON

00383505327TRLO0.1.1

22/12/2023

08:42:06

700

152

XLON

00383505328TRLO0.1.1

22/12/2023

08:42:06

66

152

XLON

00383505329TRLO0.1.1

22/12/2023

08:42:09

41

151.4

XLON

00383505336TRLO0.1.1

22/12/2023

08:42:12

25

151.4

XLON

00383505340TRLO0.1.1

22/12/2023

08:42:12

2194

151.4

XLON

00383505341TRLO0.1.1

22/12/2023

08:42:14

279

152

AQXE

00383505343TRLO0.1.1

22/12/2023

08:49:01

29

152

AQXE

00383506262TRLO0.1.1

22/12/2023

08:49:54

279

152

AQXE

00383506365TRLO0.1.1

22/12/2023

08:55:41

372

151.4

AQXE

00383507218TRLO0.1.1

22/12/2023

08:55:41

96

151.2

BATE

00383507219TRLO0.1.1

22/12/2023

08:55:41

893

151.4

CHIX

00383507220TRLO0.1.1

22/12/2023

08:55:41

144

151.2

BATE

00383507221TRLO0.1.1

22/12/2023

08:55:41

217

151.2

BATE

00383507222TRLO0.1.1

22/12/2023

08:55:41

412

151.2

BATE

00383507223TRLO0.1.1

22/12/2023

08:55:41

261

151.2

BATE

00383507224TRLO0.1.1

22/12/2023

08:55:41

237

151.4

CHIX

00383507225TRLO0.1.1

22/12/2023

08:55:41

1813

151

XLON

00383507226TRLO0.1.1

22/12/2023

08:55:41

52

151.4

TRQX

00383507227TRLO0.1.1

22/12/2023

08:55:41

447

151

XLON

00383507229TRLO0.1.1

22/12/2023

08:55:41

142

151.4

TRQX

00383507228TRLO0.1.1

22/12/2023

08:55:41

142

151.4

TRQX

00383507230TRLO0.1.1

22/12/2023

08:55:41

52

151.4

TRQX

00383507231TRLO0.1.1

22/12/2023

08:55:47

279

151

CHIX

00383507247TRLO0.1.1

22/12/2023

09:07:47

1148

150.8

CHIX

00383509008TRLO0.1.1

22/12/2023

09:07:47

84

151

CHIX

00383509009TRLO0.1.1

22/12/2023

09:13:32

990

151.8

CHIX

00383509915TRLO0.1.1

22/12/2023

09:13:32

194

151.8

TRQX

00383509917TRLO0.1.1

22/12/2023

09:13:32

1695

151.8

XLON

00383509916TRLO0.1.1

22/12/2023

09:47:30

57

153.2

BATE

00383514659TRLO0.1.1

22/12/2023

09:49:22

372

152.2

AQXE

00383515070TRLO0.1.1

22/12/2023

09:49:22

865

152.2

BATE

00383515071TRLO0.1.1

22/12/2023

09:49:22

1130

152.2

CHIX

00383515072TRLO0.1.1

22/12/2023

09:49:22

1695

152.2

XLON

00383515073TRLO0.1.1

22/12/2023

09:49:22

194

152.2

TRQX

00383515074TRLO0.1.1

22/12/2023

10:41:15

140

151.4

BATE

00383521458TRLO0.1.1

22/12/2023

10:54:43

48

152.6

AQXE

00383524055TRLO0.1.1

22/12/2023

10:54:43

68

152.6

AQXE

00383524056TRLO0.1.1

22/12/2023

10:55:17

279

152.6

AQXE

00383524175TRLO0.1.1

22/12/2023

11:00:35

565

151.6

BATE

00383525058TRLO0.1.1

22/12/2023

11:00:35

785

151.6

AQXE

00383525057TRLO0.1.1

22/12/2023

11:00:35

1130

151.6

CHIX

00383525059TRLO0.1.1

22/12/2023

11:00:35

2260

151.6

XLON

00383525060TRLO0.1.1

22/12/2023

11:00:35

194

151.6

TRQX

00383525061TRLO0.1.1

22/12/2023

11:04:59

1130

151.8

CHIX

00383525860TRLO0.1.1

22/12/2023

11:08:55

464

151.8

CHIX

00383526673TRLO0.1.1

22/12/2023

11:36:23

869

153.6

XLON

00383530857TRLO0.1.1

22/12/2023

11:36:23

710

153.6

XLON

00383530858TRLO0.1.1

22/12/2023

11:36:26

412

153.6

XLON

00383530877TRLO0.1.1

22/12/2023

11:36:34

482

153.6

XLON

00383530899TRLO0.1.1

22/12/2023

11:36:38

259

153.6

XLON

00383530905TRLO0.1.1

22/12/2023

11:36:42

330

153.6

XLON

00383530912TRLO0.1.1

22/12/2023

11:36:58

71

154.2

CHIX

00383531014TRLO0.1.1

22/12/2023

11:37:31

990

158.6

BATE

00383531075TRLO0.1.1

22/12/2023

11:37:51

440

158.2

CHIX

00383531113TRLO0.1.1

22/12/2023

11:37:51

250

158.2

CHIX

00383531114TRLO0.1.1

22/12/2023

11:37:51

586

158.2

XLON

00383531116TRLO0.1.1

22/12/2023

11:37:51

3173

158.2

XLON

00383531115TRLO0.1.1

22/12/2023

11:37:51

371

158.2

XLON

00383531117TRLO0.1.1

21/12/2023

16:29:51

64

150.6

XLON

00383452416TRLO0.1.1

21/12/2023

16:29:55

153

150.6

TRQX

00383452507TRLO0.1.1

21/12/2023

16:29:55

329

150.6

XLON

00383452508TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings